Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
OncoSil Medical Ltd ( (AU:OSL) ) just unveiled an announcement.
OncoSil Medical announced that a peer‑reviewed study in Gastrointestinal Endoscopy found that patients with locally advanced pancreatic cancer treated with the OncoSil™ phosphorus‑32 implant plus chemotherapy experienced better outcomes than those receiving chemotherapy alone, with improved overall survival, longer local progression‑free survival, higher rates of tumour downstaging and surgical resection, and a favourable safety profile in a 104‑patient analysis. The study, conducted by teams in Australia and New Zealand and accompanied by a positive independent editorial describing the results as “a signal worth pursuing,” strengthens the clinical evidence base for OncoSil™ therapy and supports the company’s ongoing clinical development efforts, potentially enhancing its positioning in the pancreatic cancer treatment landscape and offering encouraging signals for clinicians and patients facing limited options.
The most recent analyst rating on (AU:OSL) stock is a Sell with a A$1.00 price target. To see the full list of analyst forecasts on OncoSil Medical Ltd stock, see the AU:OSL Stock Forecast page.
More about OncoSil Medical Ltd
OncoSil Medical Limited is an Australian medical device company focused on localized treatments for patients with unresectable locally advanced pancreatic cancer, developing its OncoSil™ phosphorus-32 implant as an adjunct to standard chemotherapy to improve outcomes in this hard-to-treat indication.
Average Trading Volume: 21,452
Technical Sentiment Signal: Sell
Current Market Cap: A$17.57M
See more insights into OSL stock on TipRanks’ Stock Analysis page.